Tivic Health (TIVC) Q4 2025 earnings review
A Complete Rebirth Financed by Heavy Dilution
Tivic has completely abandoned its past. The legacy ClearUP consumer business is officially discontinued, and shockingly, the highly-promoted VNS neuromodulation program has been suspended. The company is now a pure-play immunotherapy and contract manufacturing (CDMO) bet. To solve a critical third-party manufacturing delay flagged in Q3, management took on a massive $16.3 million convertible note to acquire their own facility (Velocity Bioworks) and hire 45 employees. Cash surged to $12.6 million, but the operating profile is accelerating into a high-burn state with net losses expected to hit $9.1 million for the year.
🐂 Bull Case
The Q3 crisis involving a stressed contract manufacturer is resolved. Creating Velocity Bioworks vertically integrates Entolimod production and opens a potential third-party revenue stream.
With the consumer business wound down and VNS suspended, 100% of focus and capital is now dedicated to securing BARDA/DoD funding for Entolimod as a medical countermeasure.
🐻 Bear Case
The company went from zero debt all year to carrying a $16.3 million Senior Secured Convertible Note, introducing severe dilution risk and a complex capital structure.
In Q1 and Q2, management touted '400% efficacy improvements' and 'surprise findings' for the VNS program. Suspending it entirely a few months later suggests wasted R&D and raises questions about prior strategic claims.
⚖️ Verdict: 🔴
Bearish. While vertical integration logically solves their supply chain woes, the sudden suspension of a core pipeline asset (VNS) and the introduction of $16.3M in convertible debt transforms Tivic into a highly speculative, high-burn entity with zero current revenue.
Key Themes
The Abrupt Reversal of the VNS Program
The suspension of the non-core neuromodulation (VNS) program is a reversing trend that contradicts the company's prior narrative. In previous quarters, management heavily promoted VNS as a second growth pillar, citing new intellectual property and imminent clinical trials. Completely abandoning it forces investors to write off significant R&D spend and places the entirety of the company's valuation squarely on Entolimod.
Solving Supply Chain Woes with Extreme Leverage
In Q3, management flagged that their contract manufacturer was under 'financial stress,' delaying Entolimod's critical GMP validation. The solution was drastic: Tivic took on a $16.3 million Senior Secured Convertible Note in December to acquire biomanufacturing assets, forming Velocity Bioworks. This instantly pivots the company from a debt-free balance sheet to highly leveraged, dramatically changing the risk profile.
Velocity Bioworks as a CDMO Revenue Engine
Management intends to operate Velocity Bioworks as a standalone CDMO to service third-party projects. With 45 new employees hired in December, this facility must quickly generate cash to offset its high fixed costs. If successful, it transforms Tivic's manufacturing from a pure cost center into a high-margin revenue stream.
Government Funding Remains the Primary Catalyst
Discussions are actively ongoing with BARDA, DTRA, and NIAID regarding Entolimod's deployment as a medical countermeasure for Acute Radiation Syndrome. Securing non-dilutive government funding or a Strategic National Stockpile contract remains the single most important binary event for the stock.
Oncology Expansion: The Neutropenia Target
Beyond biodefense, Tivic is positioning Entolimod (and next-gen Entolasta) for oncology supportive care. By targeting neutropenia (severe side effects of chemo/radiation), the company is addressing a multi-billion-dollar commercial market. Management expects to advance this into physician-sponsored clinical trials later in 2026.
Other KPIs
Accelerating. Up from $4.5 million in FY24. The massive increase reflects the addition of the biopharma business in February and the aggressive onboarding of 45 CDMO employees in December. Investors should expect this run-rate to climb significantly higher in 2026.
Accelerating. Up from a $5.7 million loss in 2024. $900,000 of the 2025 loss is attributed to discontinued operations (the wind-down of the ClearUP consumer business), meaning the core biopharma burn is running at approximately $8 million annually before the full weight of the new CDMO payroll hits.
Reversing. Up significantly from previous quarters, entirely funded by the $16.3 million convertible debt issuance. This provides the near-term runway needed to reach Entolimod manufacturing validation and initiate Phase II oncology trials.
Guidance
Management expects to advance the Entolimod/Entolasta program into physician-sponsored clinical trials for Neutropenia later this year. This represents an acceleration from pre-clinical planning into active human oncology trials.
Key Questions
VNS Program Suspension
In previous quarters, you cited '400% improvements' and 'surprise findings' regarding the VNS program. What specific data or strategic shift caused you to suddenly suspend this asset entirely?
Convertible Note Terms
Can you provide specifics on the conversion price, interest rate, and maturity of the $16.3 million Senior Secured Convertible Note? How are you protecting existing shareholders from a potential death spiral dilution?
Velocity Bioworks Revenue Timeline
You highlighted Velocity Bioworks as an 'immediate opportunity for a new revenue stream.' When do you expect to sign your first third-party CDMO contract, and what is the expected cash burn of this facility until it reaches break-even?
Government Contract Timing
With the manufacturing bottleneck supposedly solved in-house, what is the realistic, updated timeline for formalizing a stockpile or funding agreement with BARDA or the DoD?